Clinical

An examination of patient outcomes from the ZUMA-2 trial creates new questions about treatment sequencing.

Individuals can use these 5 ways to minimize their cancer risk during National Cancer Prevention Month and beyond.

Epcoritamab delivers lasting 3-year remissions in relapsed large B-cell lymphoma, with over half of complete responders staying progression-free.

Jordan Karlitz, MD, explains the rise in CRC-related deaths in younger adults, stressing the need for earlier screening and symptom awareness.

Biagio Ricciuti, MD, discusses how access challenges and toxicity concerns slow the rollout of new T-cell engager therapies from academic centers into community oncology.

Kavita Nair, PhD, discusses integrating neurology and pharmacy services to improve MS care coordination and reduce treatment delays.

Vishal A. Patel, MD, shares skin cancer prevention tips, highlighting sun-smart habits, risk-based screening, and at-home early detection.

The combination regimen is so effective because DAC has several mechanisms through which it exerts antileukemic effects.

The visual nature of head and neck cancer calls for treatment strategies that will minimize toxicities related to radiation therapy. Advances in precision radiation techniques, supportive care, and multidisciplinary approaches have improved outcomes, improving quality of life.

As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.

This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted next-generation sequencing (NGS) panels.

A stronger effect on neovascular age-related macular degeneration (nAMD) was found with faricimab vs aflibercept.

Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.

The test was more likely to have a positive response in patients with a decrement after nerve stimulation.

This article highlights challenges in prior authorization and offers practical, experience-based strategies to streamline workflows, reduce delays, and improve patient access to necessary treatments.

This episode examines the barriers to accessing HER2-targeted therapies for non-small cell lung cancer (NSCLC) and strategies to overcome them. The discussion highlights the importance of aligning with payer requirements and clinical guidelines, such as those from NCCN, to facilitate insurance approval of recently FDA-approved HER2-targeted treatments.

Experts discuss the FDA's Accelerated Approval Program, emphasizing its role in providing earlier access to innovative cancer therapies for patients.

A review updates MASH diagnosis and prognosis guidelines, highlighting noninvasive scores, imaging, and emerging therapies, plus lifestyle strategies to improve outcomes.

Vishal A. Patel, MD, explains that delayed skin cancer diagnoses contribute to more advanced disease and poorer outcomes in patients with darker skin.

Osama Abdelghany, PharmD, explains how medically integrated dispensing improves oncology workflows, patient access, and outcomes through EMR-driven care.

Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.

Community partnerships and trial design reforms can reduce travel barriers and improve underserved patient representation, said Amir Fathi, MD.

Experts discuss the importance of transitioning cancer care from academic centers to community settings, ensuring effective patient management and support.

Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient support and effective communication.

Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.